Clarus Ventures

Co-founders Nick Galakatos and Dennis Henner sit at the top of the investment committee alongside Managing Directors Scott Requadt and Kurt Wheeler. The four partners make investment decisions collectively, drawing on their combined operating experience at firms like Novartis, Genentech, and Biogen. No single partner holds unilateral decision-making authority based on public disclosures.

Clarus sources opportunities through deep relationships with academic medical centers in Boston and San Francisco, where both offices sit within walking distance of MIT, Harvard, Stanford and UCSF. The firm's partners regularly consult for research institutions, review unpublished data, and co-found companies alongside academic investigators before competitive Series A processes formally launch. This pre-formation engagement model generates deal flow that generalist VCs rarely see.

Clarus concentrates on Series A and Series B rounds where clinical or preclinical data exists but the company has not yet entered large-scale pivotal trials. The firm routinely leads or co-leads these rounds, taking board seats and helping recruit management teams. Clarus does not invest at the seed stage or in public-company PIPEs based on its disclosed fund strategy.

Clarus operates as a direct investor, taking equity positions in private biotechnology and diagnostics companies through its flagship fund vehicles. There is no public record of the firm making LP commitments to other venture capital funds. The strategy is exclusively direct and concentrated, with a finite number of portfolio positions per fund.

Clarus does not invest outside human therapeutics, diagnostics, and enabling life-sciences technologies. The firm has never made a medical device, health IT, or healthcare services investment based on disclosed portfolio companies. This therapeutic-only focus differentiates Clarus from broad healthcare funds that span devices, services, and digital health.

Clarus is an institutional asset manager, not a family office — its limited partners include university endowments, philanthropic foundations, public pension funds, and sovereign wealth funds. The firm's own SEC filings and fundraising disclosures confirm no single-family or individual anchor LP. The partnership economics belong to the named managing directors.

Clarus is a direct competitive spinout: Nick Galakatos and Dennis Henner were both managing directors at MPM Capital before leaving in 2005 to launch their own life-sciences firm. No ongoing economic or strategic partnership between the two firms has been publicly disclosed. Clarus operates completely independently of MPM.